Treatment of pelvic pain associated with endometriosis

doi:10.1016/j.fertnstert.2008.08.057

Cited by 96 publications

(43 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combined oral contraceptives, while widely used to manage symptoms of endometriosis, are not approved for this indication in most countries and their use is largely unsupported by solid clinical trial evidence [4]. One study has demonstrated that the use of a low-dose oral contraceptive pill is an effective treatment for dysmenorrhea associated with endometriosis [5].…”

Section: Introductionmentioning

confidence: 99%

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Petraglia

Hornung²,

Seitz

et al. 2011

Arch Gynecol Obstet

162

127

View full text Add to dashboard Cite

PurposeTo investigate the efficacy and safety of dienogest as a long-term treatment in endometriosis, with follow-up after treatment discontinuation. The study included women with endometriosis, who had previously completed a 12-week, placebo-controlled study of dienogest, who participated in an open-label extension study for up to 53 weeks. Thereafter, a patient subgroup was evaluated in a 24-week follow-up after treatment discontinuation.MethodsA multicenter study performed in Germany, Italy and Ukraine. Women with endometriosis were enrolled at completion of the placebo-controlled study (n = 168). All women received dienogest (2 mg once daily, orally) and changes in pelvic pain (on a visual analog scale), bleeding pattern, adverse events and laboratory parameters were evaluated during and after treatment.ResultsThe completion rate among women who entered the open-label extension study was 90.5% (n = 152). A significant decrease in pelvic pain was shown during continued dienogest treatment (P < 0.001). The mean frequency and intensity of bleeding progressively decreased. Adverse events, rated generally mild or moderate, led to withdrawal in four patients (2.4%). No clinically relevant changes in laboratory parameters were observed. During treatment-free follow-up (n = 34), the reduction in pelvic pain persisted, while bleeding frequency and intensity returned to normal patterns.ConclusionsLong-term dienogest showed a favorable efficacy and safety profile, with progressive decreases in pain and bleeding irregularities during continued treatment; the decrease of pelvic pain persisted for at least 24 weeks after treatment cessation.

show abstract

Section: Introductionmentioning

confidence: 99%

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Petraglia

Hornung²,

Seitz

et al. 2011

Arch Gynecol Obstet

162

127

View full text Add to dashboard Cite

show abstract

“…Women suffering from endometriosis may be treated with oral contraceptives or in severe cases by hysterectomy, which have both been observed in other studies to be associated with increased risk of PD 7,37. Further study, including prescription and treatment information, would be warranted for these findings.…”

Section: Discussionmentioning

confidence: 79%

Estrogen-related and other disease diagnoses preceding Parkinson’s disease

Latourelle

Dybdahl²,

DeStefano³

et al. 2010

CLEP

View full text Add to dashboard Cite

Purpose:Estrogen exposure has been associated with the occurrence of Parkinson’s disease (PD), as well as many other disorders, and yet the mechanisms underlying these relations are often unknown. While it is likely that estrogen exposure modifies the risk of various diseases through many different mechanisms, some estrogen-related disease processes might work in similar manners and result in association between the diseases. Indeed, the association between diseases need not be due only to estrogen-related factors, but due to similar disease processes from a variety of mechanisms.Patients and methods:All female Parkinson’s disease cases between 1982 and 2007 (n = 12,093) were identified from the Danish National Registry of Patients, along with 10 controls matched by years of birth and enrollment. Conditional logistic regressions (CLR) were used to calculate risk of PD after diagnosis of the estrogen-related diseases, endometriosis and osteoporosis, conditioning on years of birth and enrollment. To identify novel associations between PD and any other preceding conditions, CLR was also used to calculate the odds ratios (ORs) for risk of PD for 202 different categories of preceding disease diagnoses. Empirical Bayes methods were used to identify the robust associations from the over 200 associations produced by this analysis.Results:We found a positive association between osteoporosis and osteoporotic fractures and PD (OR = 1.18, 95% confidence interval [CI] of 1.08–1.28), while a lack of association was observed between endometriosis and PD (OR = 1.37, 95% CI 0.99–1.90). Using empirical Bayes analyses, 24 additional categories of diseases, likely unrelated to estrogen exposure, were also identified as potentially associated with PD.Conclusion:We identified several novel associations, which may provide insight into common causal mechanisms between the diseases or greater understanding of potential early preclinical signs of PD. In particular, the associations with several categories of mental disorders suggest that these may be early warning signs of PD onset or these diseases (or the causes of these diseases) may predispose to PD.

show abstract

“…Препаратом первой линии для долговремен-ного лечения болевого синдрома при эндометриозе можно считать диеногест 2 мг. Согласно рекоменда-циям SOGC Clinical Practice Guideline [1,7,8,10,27,28,30,31], монотерапия прогестинами внутрь отно-сится к первой линии терапии, а терапия а-ГнРГ в комбинации с заместительной гормональной тера-пией в качестве возвратной терапии является тера-пией второй линии.…”

Section: выводыunclassified

Life quality of patients with endometriosis

Сонова¹,

Loginova²,

Arslanyan³

et al. 2015

Probl. reprod.

View full text Add to dashboard Cite

Основными вопросами для врачей являются во-просы этиологии, патогенеза, прогноза и лечения эндометриоза. Для больных и их родственников, на-против, важны социальные аспекты заболевания (Sutton, Beran, 1981). Влияние эндометриоза на со-циальную активность очень разнообразно. В то вре-мя как некоторые больные эндометриозом практи-чески не имеют никаких социальных проблем, дру-гие испытывают серьезные трудности, вследствие которых не могут вести полноценную в социальном смысле жизнь [21,24,25,36,37]. Принципиально значимыми социальными аспектами при эндоме-триозе являются: влияние заболевания на трудовую e-mail: sonova@rambler.ru деятельность и образование, работоспособность, от-ношения с окружающими, отношения с детьми, ко-торые складываются в составляющие качества жиз-ни [5,6,17,22,23,29,35,38]. Показано, что степень социальной дисфункции выше у больных с болевым синдромом в разных его проявлениях в сравнении с больными, не имеющими болевого синдрома [2,4,7,9]. Социальное функционирование является одной из главных составляющих качества жизни. В послед-ние годы отмечается прогрессивный рост интереса к понятию качества жизни и увеличение публикаций по данной проблеме. Согласно определению ВОЗ, качество жизни -состояние полного физического, Цель исследования -изучение качества жизни пациенток с эндометриозом до и после лечения. Материал и методы. Проведено анкетирование 140 пациенток с целью изучения параметров КЖ пациенток с эндометриозом, а также прослежены изменения этих параметров после комплексного лечения (препаратами диеногест и а-ГнРГ). Результаты. Качество жизни женщин с эндометриозом значительно снижено по сравнению со здоровыми женщинами. Не отмечено статистических различий между двумя группами при лечении болевого синдрома диеногестом и трипторелином в снижении оценок болевого синдрома по ВАШ. Диеногест и а-ГнРГ одинаково эффективны в лечении болевого синдрома в течение 6 мес. Выводы. Препаратом первой линии для долговременного лечения болевого синдрома при эндометриозе можно считать диеногест 2 мг. Болевой синдром у пациенток с эндометриозом наиболее удобно оценивать количественно с использованием Визуальной аналоговой шкалы (ВАШ) в процессе лечения, что является параметром контроля проводимой терапии для врача и его пациентки. Терапия эндометриоза должна быть долговременной с целью предупреждения рецидивов заболевания и улучшения показателей качества жизни больных. Objective. To study the life quality in patients with endometriosis before and after the treatment. Material and methods. We interviewed 140 patients to investigate the parameters of life quality with endometriosis and their changes after complex treatment with deinogest and aGnRH. Results. The life quality in patients with endometriosis is much lower compared with healthy women. No statistical difference was found for 6 months of pain control treatment according to VAS (visual analog scale) between dienogest or triptorelin groups. Conclusion. We consider dienogest 2 mg is the first line of long-term treatment of pain control syndrome for wo...

show abstract

Treatment of pelvic pain associated with endometriosis

Abstract: Pain associated with endometriosis requires careful evaluation to exclude other potential causes and may involve a number of different mechanisms. Both medical and surgical treatments for pain related to endometriosis are effective and choice of treatment must be individualized.

Cited by 96 publications

References 82 publications

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Estrogen-related and other disease diagnoses preceding Parkinson’s disease

Life quality of patients with endometriosis

Contact Info

Product

Resources

About

Treatment of pelvic pain associated with endometriosis

Abstract: Pain associated with endometriosis requires careful evaluation to exclude other potential causes and may involve a number of different mechanisms. Both medical and surgical treatments for pain related to endometriosis are effective and choice of treatment must be individualized.

Cited by 96 publications

References 82 publications

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment

Estrogen-related and other disease diagnoses preceding Parkinson&rsquo;s disease

Life quality of patients with endometriosis

Contact Info

Product

Resources

About

Estrogen-related and other disease diagnoses preceding Parkinson’s disease